Different anesthetic sensitivities of skeletal and cardiac isoforms of the Ca-ATPase.
We have previously shown that low levels of the volatile anesthetic halothane activate the Ca-ATPase in skeletal sarcoplasmic reticulum (SR), but inhibit the Ca-ATPase in cardiac SR. In this study, we ask whether the differential inhibition is due to (a) the presence of the regulatory protein phospholamban in cardiac SR, (b) different lipid environments in skeletal and cardiac SR, or (c) the different Ca-ATPase isoforms present in the two tissues. By expressing skeletal (SERCA 1) and cardiac (SERCA 2a) isoforms of the Ca-ATPase in Sf21 insect cell organelles, we found that differential anesthetic effects in skeletal and cardiac SR are due to differential sensitivities of the SERCA 1 and SERCA 2a isoforms to anesthetics. Low levels of halothane inhibit the SERCA 2a isoform of the Ca-ATPase, and have little effect on the SERCA 1 isoform. The biochemical mechanism of halothane inhibition involves stabilization of E2 conformations of the Ca-ATPase, suggesting direct anesthetic interaction with the ATPase. This study establishes a biochemical model for the mechanism of action of an anesthetic on a membrane protein, and should lead to the identification of anesthetic binding sites on the SERCA 1 and SERCA 2a isoforms of the Ca-ATPase.
Karon
B S
BS
Department of Biochemistry, University of Minnesota Medical School, Minneapolis 55455, USA.
Autry
J M
JM
Shi
Y
Y
Garnett
C E
CE
Inesi
G
G
Jones
L R
LR
Kutchai
H
H
Thomas
D D
DD
D018685:Anesthetics, Inhalation / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002118:Calcium / Q000502:physiology; D002135:Calcium-Binding Proteins / Q000276:immunology; D000252:Calcium-Transporting ATPases / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism*; D002462:Cell Membrane / Q000187:drug effects / Q000201:enzymology; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006221:Halothane / Q000494:pharmacology*; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology*; D009206:Myocardium / Q000201:enzymology*; D010710:Phosphates / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011487:Protein Conformation / Q000187:drug effects; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism; D011817:Rabbits; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000201:enzymology; D000099211:Phospholamban
D018685:Anesthetics, Inhalation; D000911:Antibodies, Monoclonal; D002118:Calcium; D002135:Calcium-Binding Proteins; D000252:Calcium-Transporting ATPases; D004791:Enzyme Inhibitors; D006221:Halothane; D010710:Phosphates; D020033:Protein Isoforms; D000099211:Phospholamban